CELLDEX THERAPEUTICS INC NEW's ticker is CLDX and the CUSIP is 15117B202. A total of 116 filers reported holding CELLDEX THERAPEUTICS INC NEW in Q1 2021. The put-call ratio across all filers is 0.66 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,147 | +1185.6% | 78,011 | +1481.7% | 0.02% | +2400.0% |
| Q2 2023 | $167 | -55.3% | 4,932 | -52.5% | 0.00% | -75.0% |
| Q1 2023 | $374 | +23.4% | 10,389 | +52.7% | 0.00% | 0.0% |
| Q4 2022 | $303 | -99.9% | 6,802 | -47.9% | 0.00% | -20.0% |
| Q3 2022 | $367,000 | -75.6% | 13,068 | -76.6% | 0.01% | -68.8% |
| Q2 2022 | $1,503,000 | +216.4% | 55,755 | +299.4% | 0.02% | +433.3% |
| Q1 2022 | $475,000 | +21.8% | 13,960 | +38.4% | 0.00% | +50.0% |
| Q4 2021 | $390,000 | -63.1% | 10,087 | -48.5% | 0.00% | -60.0% |
| Q3 2021 | $1,057,000 | +140.2% | 19,574 | -22.0% | 0.01% | +150.0% |
| Q4 2020 | $440,000 | – | 25,103 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Kynam Capital Management, LP | 3,200,000 | $88,064,000 | 14.40% |
| Octagon Capital Advisors LP | 759,898 | $20,912,393 | 3.21% |
| TSP Capital Management Group, LLC | 251,695 | $6,926,645 | 2.67% |
| 5AM Venture Management, LLC | 310,270 | $8,538,630 | 2.46% |
| COMMODORE CAPITAL LP | 706,665 | $19,447,421 | 2.27% |
| ACUTA CAPITAL PARTNERS, LLC | 122,341 | $3,366,824 | 2.26% |
| Redmile Group, LLC | 1,635,938 | $45,021,014 | 2.14% |
| RTW INVESTMENTS, LP | 3,463,201 | $95,307,292 | 2.01% |
| Eversept Partners, LP | 588,143 | $16,185,695 | 1.37% |
| Affinity Asset Advisors, LLC | 150,000 | $4,128,000 | 1.16% |